391 related articles for article (PubMed ID: 33632314)
1. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
4. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance and prognostic value of preoperative
Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
[TBL] [Abstract][Full Text] [Related]
6. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic performance of
Nakanishi Y; Kitajima K; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K; Yamamoto S
Ann Nucl Med; 2018 Dec; 32(10):658-668. PubMed ID: 30120698
[TBL] [Abstract][Full Text] [Related]
10. Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison
Kitajima K; Yamamoto S; Kawanaka Y; Katsuura T; Fujita M; Nakanishi Y; Yamada Y; Hashimoto T; Suzuki T; Go S; Kanematsu A; Nojima M; Yamakado K
Jpn J Radiol; 2019 Feb; 37(2):165-177. PubMed ID: 30377936
[TBL] [Abstract][Full Text] [Related]
11. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy.
Nakaigawa N; Kondo K; Ueno D; Namura K; Makiyama K; Kobayashi K; Shioi K; Ikeda I; Kishida T; Kaneta T; Minamimoto R; Tateishi U; Inoue T; Yao M
BMC Cancer; 2017 Jan; 17(1):39. PubMed ID: 28068944
[TBL] [Abstract][Full Text] [Related]
12. Semi-quantitative F-18-FDG PET/computed tomography parameters for prediction of grade in patients with renal cell carcinoma and the incremental value of diuretics.
Singh H; Arora G; Nayak B; Sharma A; Singh G; Kumari K; Jana S; Patel C; Pandey AK; Seth A; Kumar R
Nucl Med Commun; 2020 May; 41(5):485-493. PubMed ID: 32168262
[TBL] [Abstract][Full Text] [Related]
13. Restaging [
Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.
Nakajima R; Abe K; Kondo T; Tanabe K; Sakai S
Eur Radiol; 2016 Jun; 26(6):1852-62. PubMed ID: 26403580
[TBL] [Abstract][Full Text] [Related]
15. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
16. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
[TBL] [Abstract][Full Text] [Related]
17. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of [68Ga]Ga-fibroblast activation protein inhibitor-04 PET/CT in renal cell carcinoma.
Guo C; Liu Y; Yang H; Xia Y; Li X; Chen L; Feng Y; Zhang Y; Chen Y; Huang Z
Br J Radiol; 2024 Mar; 97(1156):859-867. PubMed ID: 38290775
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
